BenevolentAI Investor Conference Presentation Deck
The Benevolent Platform™
Built for Scientists by Scientists
Ingestion &
Insight Extraction
85+ data sources,
Structured
Ontologies & Databases etc.
Unstructured (NLP)
Literature, Patents, Trials etc.
Genetics & Omics
sc (RNASeq), Epigenetics etc.
Clinical
Biobank, Partner cohorts etc..
Experimental
ELNS, Assay results etc.
Chemistry
Binding, structural, MoA etc.
Protein Structure
Binding site analysis etc.
Data Integration
& Inference
Comprehensive foundations
reduce bias & gaps, breaking
down therapeutic silos
Data Foundations
(Knowledge Graph)
Al-Driven Drug Discovery Revenue Streams
& Development
Al technologies applied to specific DD
problems + state of art wet lab and
scientific capabilities
. Clinical Subtyping
. Mechanism
Recommendation
• Target Prediction &
Assessment
Experimental
hypothesis validation
●
• In silico led HitID
• In silico led LeadOp
. Biomarker
Assessment
• Indication and Drug
Repurposing
BenevolentAl Proprietary
Benevolent PlatformTM
provides multiple
opportunities
End-to-end
drug discovery
Preclinical &
Clinical
Development
Pipeline
Knowledge
Exploration
Tools
Novel insights from
public, proprietary, &
inferred knowledge
✔ Unique data
foundations from multiple
data types curated and
purpose-built for drug
discovery
Explainable Al models
enable scientists to see
rationale for predictions
✔ Applicable across
therapeutic areas and
modalities
Benevolent
4View entire presentation